Loading data for JUNS — first visit, this takes a few seconds.
Jupiter Neurosciences, Inc. (JUNS)
NasdaqCM: JUNS
· Real-Time Price · USD
4.18
-0.71 (-14.52%)
At close: Sep 04, 2026, 8:00 PM
3.28
+0.00%
After-hours: 7:30 PM
The price, the headline numbers and the latest news, in one place.
Jupiter Neurosciences, Inc. (JUNS) Stock Price, Analysis & Data
No data available
| Bid | 5.33 |
| Market Cap | 4.32M |
| Revenue (ttm) | 64.7K |
| Net Income (ttm) | -9.2M |
| 0.00 | |
| -19.07 | |
| n/a | |
| 54.67 | |
| P/B (ttm) | -0.57 |
| P/S (ttm) | 66.85 |
| Earnings Date | n/a |
| Ask | 5.35 |
| Volume | 204,251 |
| Avg. Volume (20D) | 991,079 |
| Open | 5.15 |
| Previous Close | 4.89 |
| Day's Range | 4.10 - 5.15 |
| 52-Week Range | 4.10 - 138.00 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About JUNS
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson's disease; ...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 3, 2024
Employees 5
Stock Exchange NasdaqCM
Ticker Symbol JUNS
Website https://jupiterneurosciences.com
Financial Performance
In 2025, Jupiter Neurosciences's revenue was 21.8K, an increase of undefined% compared to the previous year's 0. Earnings were -8.64M, an increase of 254.35%.
Financial StatementsEarnings Surprise
Jupiter Neurosciences has released their quarterly earnings on Nov 14, 2025:
- Revenue of $18.65K misses estimates by $0, with Infinity% YoY growth.
- EPS of -5.25 exceeds estimates by 0.75, with -250.00% YoY decline.
Page 1 of 2